



Marksans Pharma Ltd.

Date: April 15, 2024

BSE Limited

Corporate Relation Department
Phiroze Jeejeeboi Towers,
Dalal Street,
Mumbai - 400001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.

Scrip Code: 524404

Symbol: MARKSANS

Sub: Disclosure pursuant to Chapter XII of the Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021

Dear Sir/Madam,

Pursuant to Chapter XII of the Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as amended from time to time, read with SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, on fund raising by issuance of debt securities by large corporate, kindly find enclosed **Annexure B2**, annual disclosure to be made by the Company.

We confirm that **we are not a Large Corporate** as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021, as amended.

We request you to take the aforesaid on records.

Thanking you,

Yours faithfully,
For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary

Encl: as above

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com

www.marksanspharma.com



Marksans Pharma Ltd.

Annexure B2

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate

1. Name of the Company: Marksans Pharma Limited
2. CIN: L24110MH1992PLC066364
3. Report filed for FY: 2023-24
4. Details of the current block (all figures in Rs. Crore):

Sr. No.	Particulars	Details
1.	3-year block period (specify financial years)	FY 2023-24, 2024-25 & 2025-26
2.	Incremental borrowing done in FY 2023-24 (a)	Nil
3.	Mandatory borrowing to be done through debt securities in FY 2023-24 (b) = (25% of a)	Not Applicable
4.	Actual borrowing done through debt securities in FY 2023-24 (c)	Nil
5.	Shortfall in the borrowing through debt securities, if any, for FY 2022-23 carried forward to FY 2023-24 (d)	Not Applicable
6.	Quantum of (d), which has been met from (c) = (e)	Not Applicable
7.	Shortfall, if any, in the mandatory borrowing through debt securities for FY2023-24 {after adjusting for any shortfall in borrowing for FY2022-23 which was carried forward to FY2023-24} (f) = (b) - [(c) - (e)] {If the calculated value is zero or negative, write "nil"}	Not Applicable

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs. Crore):

Sr. No	Particulars	Details
1.	3-year block period (specify financial years)	FY 2023-24, 2024-25 & 2025-26
2.	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)} [#]	Not Applicable

*In cases, where an entity is not categorised as LC for FY (T), however was LC for FY (T- 1), and there was a shortfall in the mandatory bond borrowing for FY (T-1), which was carried forward to FY (T), the disclosures as prescribed in this annexure shall be made by the entity for FY (T).

*(d) and (e) are the same as mentioned at Sr. nos. 5 and 6 in the table given at point no. 4 of this annexure

Harshvardhan Panigrahi
Company Secretary
Contact details: 022 40012000
E-mail: harshvardhan@marksanspharma.com



Jitendra Sharma
Chief Financial Officer
Contact details: 022 40012000
E-mail: jitendra@marksanspharma.com

Date: April 15, 2024

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 052 • Tel: +91 22 4001 2000 • E-mail: info@marksanspharma.com